Literature DB >> 18459124

Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species.

Daniel A Langer1, Amitava Das, David Semela, Ningling Kang-Decker, Helen Hendrickson, Steven F Bronk, Zvonimir S Katusic, Gregory J Gores, Vijay H Shah.   

Abstract

UNLABELLED: Hepatic stellate cells (HSCs) contribute to portal hypertension through multiple mechanisms that include collagen deposition, vasoconstriction, and regulation of sinusoidal structure. Under normal physiologic conditions, endothelial nitric oxide (NO) synthase-derived NO exerts paracrine effects on HSCs; however, in cirrhosis, NO generation is impaired in association with concomitant HSC activation and changes in sinusoidal structure, events that contribute significantly to the development of portal hypertension. These concepts, in combination with recent evidence that induction of HSC-selective apoptosis may represent a useful target for treatment of chronic liver disease, led us to examine if NO may further limit HSC function through apoptosis. Indeed, both NO donors and endothelial NO synthase overexpression promoted HSC apoptotic pathways. HSC death conferred by NO occurred through mitochondrial membrane depolarization and through a caspase-independent pathway. Furthermore, NO-induced apoptosis of HSC did not occur through the canonical pathways of soluble guanylate cyclase or protein nitration, but rather through the generation of superoxide and hydroxyl radical intermediates. Lastly, HSC isolated from rats after bile duct ligation were more susceptible to NO-induced apoptosis. These data indicate that NO promotes HSC apoptosis through a signaling mechanism that involves mitochondria, is mediated by reactive oxygen species, and occurs independent of caspase activation.
CONCLUSION: We postulate that NO-dependent apoptosis of HSCs may maintain sinusoidal homeostasis, and may represent an additional beneficial effect of NO donors for therapy of portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18459124      PMCID: PMC2562502          DOI: 10.1002/hep.22285

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  57 in total

Review 1.  Cellular and molecular basis of portal hypertension.

Authors:  V Shah
Journal:  Clin Liver Dis       Date:  2001-08       Impact factor: 6.126

Review 2.  Nitrosylation. the prototypic redox-based signaling mechanism.

Authors:  J S Stamler; S Lamas; F C Fang
Journal:  Cell       Date:  2001-09-21       Impact factor: 41.582

3.  NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.

Authors:  S Fiorucci; E Antonelli; O Morelli; A Mencarelli; A Casini; T Mello; B Palazzetti; D Tallet; P del Soldato; A Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 4.  Caspase-independent cell death.

Authors:  Guido Kroemer; Seamus J Martin
Journal:  Nat Med       Date:  2005-07       Impact factor: 53.440

Review 5.  Free radical biology and medicine: it's a gas, man!

Authors:  William A Pryor; Kendall N Houk; Christopher S Foote; Jon M Fukuto; Louis J Ignarro; Giuseppe L Squadrito; Kelvin J A Davies
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-04-20       Impact factor: 3.619

6.  Cellular uptake and release of two contrasting iron chelators.

Authors:  H Cable; J B Lloyd
Journal:  J Pharm Pharmacol       Date:  1999-02       Impact factor: 3.765

7.  Acidosis protects against lethal oxidative injury of liver sinusoidal endothelial cells.

Authors:  S F Bronk; G J Gores
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

8.  Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans.

Authors:  E Novo; F Marra; E Zamara; L Valfrè di Bonzo; L Monitillo; S Cannito; I Petrai; A Mazzocca; A Bonacchi; R S M De Franco; S Colombatto; R Autelli; M Pinzani; M Parola
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

9.  Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity.

Authors:  Man Jiang; Qingqing Wei; Navjotsin Pabla; Guie Dong; Cong-Yi Wang; Tianxin Yang; Sylvia B Smith; Zheng Dong
Journal:  Biochem Pharmacol       Date:  2007-01-07       Impact factor: 5.858

10.  Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation.

Authors:  C X Santos; E I Anjos; O Augusto
Journal:  Arch Biochem Biophys       Date:  1999-12-15       Impact factor: 4.013

View more
  51 in total

1.  Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.

Authors:  Amitava Das; Priyabrata Mukherjee; Sumit K Singla; Praveen Guturu; Megan C Frost; Debabrata Mukhopadhyay; Vijay H Shah; Chitta Ranjan Patra
Journal:  Nanotechnology       Date:  2010-07-08       Impact factor: 3.874

2.  Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells.

Authors:  Zhixia Dong; Lin Su; Saeed Esmaili; Tristan J Iseli; Mehdi Ramezani-Moghadam; Liangshuo Hu; Aimin Xu; Jacob George; Jianhua Wang
Journal:  J Mol Med (Berl)       Date:  2015-07-09       Impact factor: 4.599

3.  Type II cyclic guanosine monophosphate-dependent protein kinase inhibits Rac1 activation in gastric cancer cells.

Authors:  Ying Wang; Yongchang Chen; Min Wu; Ting Lan; Yan Wu; Yueying Li; Hai Qian
Journal:  Oncol Lett       Date:  2015-05-04       Impact factor: 2.967

4.  miRNA studies in in vitro and in vivo activated hepatic stellate cells.

Authors:  Gunter Maubach; Michelle Chin Chia Lim; Jinmiao Chen; Henry Yang; Lang Zhuo
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

5.  Apoptosis and hepatic necroinflammation.

Authors:  Gregory J Gores
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-06

Review 6.  Antifibrotic therapies in the liver.

Authors:  W Z Mehal; D Schuppan
Journal:  Semin Liver Dis       Date:  2015-05-14       Impact factor: 6.115

7.  Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells.

Authors:  Sheng Cao; Usman Yaqoob; Amitava Das; Uday Shergill; Kumaravelu Jagavelu; Robert C Huebert; Chittaranjan Routray; Soha Abdelmoneim; Meher Vasdev; Edward Leof; Michael Charlton; Ryan J Watts; Debabrata Mukhopadhyay; Vijay H Shah
Journal:  J Clin Invest       Date:  2010-06-23       Impact factor: 14.808

8.  Inhibition of VEGF- and NO-dependent angiogenesis does not impair liver regeneration.

Authors:  U Shergill; A Das; D Langer; Rs Adluri; N Maulik; V H Shah
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05       Impact factor: 3.619

9.  Antifibrotic effects of ZK14, a novel nitric oxide-donating biphenyldicarboxylate derivative, on rat HSC-T6 cells and CCl4-induced hepatic fibrosis.

Authors:  Li Dai; Hui Ji; Xiang-wen Kong; Yi-hua Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-12-07       Impact factor: 6.150

10.  Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?

Authors:  Giovanni Tarantino; Paolo Conca; Antonio Riccio; Marianna Tarantino; Matteo N Di Minno; Domenico Chianese; Fabrizio Pasanisi; Franco Contaldo; Francesco Scopacasa; Domenico Capone
Journal:  J Transl Med       Date:  2008-11-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.